End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,405 IDR | -1.75% | +0.36% | -12.73% |
04-01 | PT Kalbe Farma Tbk. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
02-20 | Nomura Adjusts Kalbe Farma’s Price Target to IDR1,850 From IDR2,500, Keeps at Buy | MT |
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.73% | 4.01B | B+ | ||
+25.81% | 661B | C+ | ||
+26.77% | 566B | B | ||
-6.71% | 352B | C+ | ||
+20.38% | 332B | B- | ||
+2.48% | 283B | C+ | ||
+13.53% | 231B | B+ | ||
+4.80% | 200B | B- | ||
-9.33% | 195B | A+ | ||
-5.31% | 145B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- KLBF Stock
- Ratings PT Kalbe Farma Tbk.